These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 11020235

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC, Gomes BA, Rajashekara V, Patel C, Patel M.
    Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H, Wang X, Wang J, Rothman RB.
    Synapse; 2004 Jun 01; 52(3):209-17. PubMed ID: 15065220
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M, Kumar P, Sunkaraneni S, Sirohi S, Walker EA, Yoburn BC.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):92-101. PubMed ID: 17349996
    [Abstract] [Full Text] [Related]

  • 10. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
    Stafford K, Gomes AB, Shen J, Yoburn BC.
    Pharmacol Biochem Behav; 2001 Jun 01; 69(1-2):233-7. PubMed ID: 11420091
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
    Zhang Q, Purohit V, Yoburn BC.
    Synapse; 2005 Jun 01; 56(3):123-8. PubMed ID: 15765525
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL, Bartlett JL, Ananthan S, Bilsky EJ.
    J Pharmacol Exp Ther; 2001 May 01; 297(2):597-605. PubMed ID: 11303048
    [Abstract] [Full Text] [Related]

  • 15. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
    Gomes BA, Shen J, Stafford K, Patel M, Yoburn BC.
    Pharmacol Biochem Behav; 2002 May 01; 72(1-2):273-8. PubMed ID: 11900797
    [Abstract] [Full Text] [Related]

  • 16. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
    Szentirmay AK, Király KP, Lenkey N, Lackó E, Al-Khrasani M, Friedmann T, Timár J, Gyarmati S, Tóth G, Fürst S, Riba P.
    Brain Res Bull; 2013 Jan 01; 90():66-71. PubMed ID: 22995282
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Protein kinase C-mediated acute tolerance to peripheral mu-opioid analgesia in the bradykinin-nociception test in mice.
    Inoue M, Ueda H.
    J Pharmacol Exp Ther; 2000 May 01; 293(2):662-9. PubMed ID: 10773042
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.